Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements are consistent with topical use and antifungal nature, but many claims are not supported by the provided Naftin Gel FDA label excerpts (e.g., broad fungal indications beyond interdigital tinea pedis, OTC status, handwashing advice, avoiding broken skin, specific “seek care” scenarios, diabetes/circulation/immunocompromise guidance). Additionally, dosing duration differs (label excerpt specifies 2 weeks).
Category Scores
Accurate Statements
Naftifine hydrochloride cream/naftifine is an antifungal medicine used on the skin to treat fungal infections.
Supported generally by class/mechanism as antifungal; however the excerpted indication is specifically interdigital tinea pedis due to specified organisms (INDICATIONS AND USAGE; CLINICAL PHARMACOLOGY 12.4).
Topical naftifine products are typically applied once daily to the affected areas (frequency).
Apply a thin layer once daily to affected areas plus ~½ inch margin (DOSAGE AND ADMINISTRATION).
If irritation or sensitivity develops, treatment should be discontinued.
If irritation or sensitivity develops with the use of NAFTIN Gel, treatment should be discontinued (WARNINGS AND PRECAUTIONS 5.1 Local Adverse Reactions).
There is no contraindication listed for NAFTIN Gel.
None (CONTRAINDICATIONS 4).
Unsupported Statements
Naftifine hydrochloride cream is used to treat athlete’s foot (tinea pedis).
The label excerpt for NAFTIN Gel specifies interdigital tinea pedis and specific organisms; broad “tinea pedis” is not fully supported without the organism/site specificity.
Naftifine hydrochloride cream is used to treat ringworm and other superficial dermatophyte infections (tinea).
Provided indication is limited to interdigital tinea pedis caused by specified organisms (INDICATIONS AND USAGE). No ringworm/other tinea indications are included in the supplied excerpts.
Naftifine hydrochloride cream is used for some cases of cutaneous fungal infections involving the outer skin layers.
Not supported by the provided indication text (site/organism limited to interdigital tinea pedis).
Naftifine is not a treatment for bacterial infections.
No statement in the provided excerpts addresses bacterial infections (only antifungal/dermatophyte indication).
Naftifine is not a treatment for deep/systemic fungal disease.
Provided excerpts do not state any limitation regarding deep/systemic fungal disease; only ophthalmic/oral/intravaginal route is addressed (DOSAGE AND ADMINISTRATION).
Topical naftifine products are typically applied as a thin layer to clean, dry affected skin and the surrounding area.
Label excerpt specifies thin layer and ~½ inch margin, but does not mention “clean, dry” preparation.
Patients are generally advised to use topical naftifine for the full course on the package even if symptoms improve.
Label excerpt specifies treatment duration of 2 weeks, but does not include “full course even if symptoms improve” wording in provided text.
Patients are advised to wash hands after applying topical naftifine unless the hands are the treated area.
Not present in the provided label excerpts.
Patients are advised to avoid using topical naftifine on broken skin unless the product directions say it is safe.
Not present in the provided label excerpts.
Topical antifungals like naftifine can cause mild local irritation in some people.
Label supports irritation/sensitivity and postmarketing local reactions, but “like” and general mild irritation phrasing is not directly supported as written.
Topical naftifine can cause burning, stinging, redness, or itching at the application site.
These specific terms are partially supported by postmarketing reactions (burning sensation, erythema/redness, irritation, pruritus/itching, pain). “stinging” is not explicitly listed in the provided excerpts.
Using topical naftifine should be stopped and medical advice sought if significant worsening pain, swelling, blistering, or signs of allergy develop.
Label excerpt says discontinue if irritation or sensitivity develops, and postmarketing includes blisters and swelling, but does not provide this detailed “seek medical advice” decision framework.
Medical advice should be sought rather than self-treating with OTC naftifine if the rash is spreading quickly / extremely painful / oozing.
Not present in the provided label excerpts.
Medical advice should be sought if there is no improvement after about 1–2 weeks of proper use of OTC naftifine.
Label excerpt provides a 2-week application regimen and clinical assessment at week 6, but does not include an OTC “1–2 weeks if no improvement” instruction.
Medical advice should be sought if the infection keeps coming back.
Not present in the provided label excerpts.
Medical advice should be sought if the infection involves the face / genitals / large body areas.
Not present in the provided label excerpts.
Medical advice should be sought before relying on OTC naftifine if the patient has diabetes / poor circulation / a weakened immune system.
Not present in the provided label excerpts.
Medical advice should be sought if the patient suspects a different condition such as eczema, psoriasis, or a bacterial infection.
Not present in the provided label excerpts.
Generally, mixing multiple active treatments on the same spot should be avoided unless a clinician or product guidance recommends it.
No drug interaction or combination-use guidance is present in the provided excerpts.
Using harsh soaps, heavy occlusive creams, or steroid creams without guidance can sometimes worsen fungal infections or mask symptoms.
Not present in the provided label excerpts.
Naftifine hydrochloride cream OTC status may vary by brand and local drug-scheduling rules depending on where you live.
Not supported by the provided FDA label excerpts.
Checking product packaging for OTC/pharmacy availability wording can help determine whether a naftifine hydrochloride cream product is OTC.
Not supported by the provided FDA label excerpts.
Contradictions
Low
AI Statement
Topical naftifine products are typically used once daily.
Label Reference
DOSAGE AND ADMINISTRATION specifies once daily (thin layer once daily).
Important Omissions
Specific indication should be limited to interdigital tinea pedis due to Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum (INDICATIONS AND USAGE).
Importance:
Moderate
Label-specific application instructions: apply thin layer to affected areas plus ~½ inch margin of healthy surrounding skin and treat for 2 weeks (DOSAGE AND ADMINISTRATION).
Importance:
Moderate
Route limitations: for topical use only; not ophthalmic, oral, or intravaginal use (DOSAGE AND ADMINISTRATION).
Importance:
Moderate
No contraindications are listed (CONTRAINDICATIONS 4). The AI did not explicitly state “none,” though it did not contradict it.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Many detailed “seek medical advice” criteria and broad indication statements are not supported by the provided label excerpts. The main label-alignment risk is overgeneralizing the label-indicated condition beyond interdigital tinea pedis and omitting label-specific application instructions/duration and route restrictions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Overly broad fungal-indication claims (ringworm/other tinea and outer skin layers) and many practical/OTC and “seek care” instructions not supported by the provided FDA label excerpts; also missing label-specific site/organism and 2-week regimen details.
Suggested Improvement
Limit claims to NAFTIN Gel’s labeled indication (interdigital tinea pedis due to specified organisms) and include label application details (thin layer once daily to affected areas plus ~½ inch margin for 2 weeks; topical use only, not ophthalmic/oral/intravaginal). Remove or rephrase unsupported OTC/handwashing/broken skin/diabetes–circulation–immune guidance and generic decision triggers not present in the provided label excerpts.